1)Zajac, J., Kostrhunova, H., Novohradsky, V., Vrana, O., Raveendran, R., Gibson, D

1)Zajac, J., Kostrhunova, H., Novohradsky, V., Vrana, O., Raveendran, R., Gibson, D., Kasparkova, J. and Brabec, V. (2016) Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin. J. Inorg. Biochem., 156, 89-97.

2)Vrana, O., Novohradsky, V., Medrikova, Z., Burdikova, J., Stuchlikova, O., Kasparkova, J. and Brabec, V. (2016) Internalization of ineffective platinum complex in nanocapsules renders it cytotoxic. Chem. Eur. J., 22, 2728-2735.

3)Schmitt, F., Donnelly, K., Muenzner, J.K., Rehm, T., Novohradsky, V., Brabec, V., Kasparkova, J., Albrecht, M., Schobert, R. and Mueller, T. (2016) Effects of histidin-2-ylidene vs. imidazol-2-ylidene ligands on the anticancer and antivascular activity of complexes of ruthenium, iridium, platinum, and gold. J. Inorg. Biochem., in press,

4)Salem, O.M., Vilkova, M., Janockova, J., Jendzelovsky, R., Fedorocko, P., Zilecka, E., Kasparkova, J., Brabec, V., Imrich, J. and Kozurkova, M. (2016) New spiro tria(thia)zolidine-acridines as topoisomerase inhibitors, DNA binders and cytostatic compounds. Int. J. Biol. Macromol., 86, 690-700.

5)Raveendran, R., Braude, J.P., Wexselblatt, E., Novohradsky, V., Stuchlikova, O., Brabec, V., Gandin, V. and Gibson, D. (2016) Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chem. Sci., 7, 2381-2391.

6)Pracharova, J., Radosova Muchova, T., Dvorak Tomastikova, E., Intini, F.P., Pacifico, C., Natile, G., Kasparkova, J. and Brabec, V. (2016) Anticancer potential of a photoactivated transplatin derivative containing methylazaindole ligands mediated by ROS generation and DNA cleavage Dalton Trans., 45, 13179 - 13186.

7)Parajdi-Losonczi, P.L., Bényei, A.C., Kováts, É., Timári, I., Muchova, T.R., Novohradsky, V., Kasparkova, J. and Buglyó, P. (2016) [(η6-p-cymene)Ru(H2O)3]2 + binding capability of aminohydroxamates — A solution and solid state study. J. Inorg. Biochem., doi:10.1016/j.jinorgbio.2016.1002.1032.

8)Medříková, Z., Novohradsky, V., Zajac, J., Vrána, O., Kasparkova, J., Bakandritsos, A., Petr, M., Zbořil, R. and Brabec, V. (2016) Enhancing tumor cell response to chemotherapy through the targeted delivery of platinum drugs mediated by highly stable, multifunctional carboxymethylcellulose-coated magnetic nanoparticles. Chem. Eur. J., 22, 9750-9759.

9)Janockova, J., Zilecka, E., Kasparkova, J., Brabec, V., Soukup, O., Kuca, K. and Kozurkova, M. (2016) Assessment of DNA-binding affinity of cholinesterase reactivators and electrophoretic determination of their effect on topoisomerase I and II activity. Mol. BioSyst., 12, 2910-2920.

10)Brabec, V., Vrana, O., Novakova, O. and Kasparkova, J. (2016) Comment on “Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance” by H. Song, W. Li, R. Qi, L. Yan, X. Jing, M. Zheng and H. Xiao, Chem. Commun., 2015, 51, 11493. Chem. Commun., 52, 4096-4098.

11)Brabec, V., Pracharova, J., Stepankova, J., Sadler, P.J. and Kasparkova, J. (2016) Photo-induced DNA cleavage and cytotoxicity of a ruthenium(II) arene anticancer complex. J. Inorg. Biochem., 160, 149-155.

12)Brabec, V., Kasparkova, J., Kostrhunova, H. and Farrell, N.P. (2016) Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes. Sci. Rep., 6, 28474.

13)Štarha, P., Trávníček, Z., Dvořák, Z., Radošová-Muchová, T., Prachařová, J., Vančo, J. and Kašpárková, J. (2015) Potentiating effect of UVA irradiation on anticancer activity of carboplatin derivatives involving 7-azaindoles. PLoS ONE, 10, e0123595.

14)Pracharova, J., Saltarella, T., Radosova Muchova, T., Scintilla, S., Novohradsky, V., Novakova, O., Intini, F.P., Pacifico, C., Natile, G., Ilik, P., Brabec, V. and Kasparkova J. (2015) Novel antitumor cisplatin and transplatin derivatives containing 1-methyl-7-azaindole: Synthesis, characterization, and cellular responses. J. Med. Chem., 58, 847-859.

15)Patalenszki, J., Biro, L., Benyei, A.C., Muchova, T.R., Kasparkova, J. and Buglyo, P. (2015) Half-sandwich complexes of ruthenium, osmium, rhodium and iridium with dl-methionine or S-methyl-l-cysteine: a solid state and solution equilibrium study. RSC Advances, 5, 8094-8107.

16)Novohradsky, V., Zerzankova, L., Stepankova, J., Vrana, O., Raveendran, R., Gibson, D., Kasparkova, J. and Brabec, V. (2015) New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells. Biochem. Pharmacol., 95, 133-144.

17)Muenzner, J.K., Rehm, T., Biersack, B., Casini, A., de Graaf, I.A.M., Worawutputtapong, P., Noor, A., Kempe, R., Brabec, V., Kasparkova, J. et al. (2015) Adjusting the DNA interaction and anticancer activity of Pt(II) N-heterocyclic carbene complexes by steric shielding of the trans leaving group. J. Med. Chem., 58, 6283-6292.

18)Marzo, T., Pillozzi, S., Hrabina, O., Kasparkova, J., Brabec, V., Arcangeli, A., Bartoli, G., Severi, M., Lunghi, A., Totti, F. et al. (2015) cis-PtI2(NH3)2: a reappraisal. Dalton Trans., 44, 14896-14905.

19)Kasparkova, J., Kostrhunova, H., Novakova, O., Křikavová, R., Vančo, J., Trávníček, Z. and Brabec, V. (2015) A photoactivatable platinum(IV) complex targeting genomic DNA and histone deacetylases. Angew. Chem. Int. Ed., 54, 14478-14482.

20)Janočková, J., Plšíková, J., Kašpárková, J., Brabec, V., Jendželovský, R., Mikeš, J., Kovaľ, J., Hamuľaková, S., Fedoročko, P., Kuča, K. et al. (2015) Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds. Eur. J. Pharmaceut. Sci., 76, 192-202.

21)Brabec, V., Pracharova, J., Novakova, O., Gibson, D. and Kasparkova, J. (2015) The induction of lysis in lysogenic strains of Escherichia coli by a new antitumor transplatin derivative and its DNA interactions. Dalton Trans., 44, 3573–3582.

22)Novohradsky, V., Zerzankova, L., Stepankova, J., Vrana, O., Raveendran, R., Gibson, D., Kasparkova, J. and Brabec, V. (2014) Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands. J. Inorg. Biochem., 140, 72-79.

23)Novohradsky, V., Zerzankova, L., Stepankova, J., Kisova, A., Kostrhunova, H., Liu, Z., Sadler, P.J., Kasparkova, J. and Brabec, V. (2014) A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex. Metallomics, 6, 1491-1501.

24)Novohradsky, V., Liu, Z., Vojtiskova, M., Sadler, P.J., Brabec, V. and Kasparkova, J. (2014) Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand. Metallomics, 6, 682-690.

25)Kasparkova, J., Thibault, T., Kostrhunova, H., Stepankova, J., Vojtiskova, M., Midoux, P., Malinge, J.-M. and Brabec, V. (2014) Different affinity of NF-kB proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer. FEBS J., 281, 1393-1408

26)Plsikova, J., Stepankova, J., Kasparkova, J., Brabec, V., Backor, M., and Kozurkova, M. (2014). Lichen secondary metabolites as DNA-interacting agents. Toxicology in Vitro 28, 182-186.

27)Frybortova, M., Novakova, O., Stepankova, J., Novohradsky, V., Gibson, D., Kasparkova, J., and Brabec, V. (2013). Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand. J. Inorg. Biochem. 126, 46-54.

28)Muchova, T., Pracharova, J., Starha, P., Olivova, R., Vrana, O., Benesova, B., Kasparkova, J., Travnicek, Z., and Brabec, V. (2013). Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells. J. Biol. Inorg. Chem. 18, 579-589.

29)Pracharova, J., Novakova, O., Kasparkova, J., Gibson, D., and Brabec, V. (2013). Toxicity in tumor cells, DNA binding mode and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional transPtII complexes containing long alkane linkers. Pure Appl. Chem. 85, 343-354.

30)Zhao, Y., Woods, J.A., Farrer, N.J., Robinson, K.S., Pracharova, J., Kasparkova, J., Novakova, O., Li, H., Salassa, L., Pizarro, A.M., Clarkson, G.J., Song, L., Brabec, V., and Sadler, P.J. (2013). Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts. Chem. Eur. J. 19, 9578-9591.

31)Brabec, V., Griffith, D.M., Kisova, A., Kostrhunova, H., Zerzankova, L., Marmion, C.J., and Kasparkova, J. (2012). Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)]. Mol. Pharmaceutics 9, 1990-1999.

32)Brabec, V., Malina, J., Margiotta, N., Natile, G., and Kasparkova, J. (2012). Thermodynamic and mechanistic insights into translesion DNA synthesis catalyzed by Y-family DNA polymerase across a bulky double-base lesion of an antitumor platinum drug. Chem. Eur. J. 18, 15439-15448.

33)Florian, J., Kasparkova, J., Farrell, N., and Brabec, V. (2012). Thermodynamic stability and energetics of DNA duplexes containing major intrastrand cross-links of second-generation antitumor dinuclear PtII complexes. J. Biol. Inorg. Chem. 17, 187-196.

34)Mlcouskova, J., Kasparkova, J., Suchankova, T., Komeda, S., and Brabec, V. (2012). DNA conformation and repair of polymeric natural DNA damaged by antitumor azolato-bridged dinuclear PtII complex. J. Inorg. Biochem. 114, 15-23.

35)Mlcouskova, J., Malina, J., Novohradsky, V., Kasparkova, J., Komeda, S., and Brabec, V. (2012). Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear PtII complex. Biochim. Biophys. Acta 1820, 1502-1511.

36)Muchova, T., Quintal, S., Farrell, N., Brabec, V., and Kasparkova, J. (2012). Antitumor bifunctional dinuclear PtII complex BBR3535 forms interduplex DNA cross-links under molecular crowding conditions. J. Biol. Inorg. Chem. 17, 239-245.

37)Olivova, R., Stepankova, J., Muchova, T., Novohradsky, V., Novakova, O., Vrana, O., Kasparkova, J., and Brabec, V. (2012). Mechanistic insights into toxic effects of a benzotriazolate-bridged dinuclear platinum(II) compound in tumor cells. Inorg. Chim. Acta 393, 204-211.

38)Plsikova, J., Janovec, L., Koval, J., Ungvarsky, J., Mikes, J., Jendzelovsky, R., Fedorocko, P., Imrich, J., Kristian, P., Kasparkova, J., Brabec, V., and Kozurkova, M. (2012). 3,6-Bis(3-alkylguanidino)acridines as DNA-intercalating antitumor agents. Eur. J. Med. Chem. 57, 283-295.

39)Pracharova, J., Zerzankova, L., Stepankova, J., Novakova, O., Farrer, N.J., Sadler, P.J., Brabec, V., and Kasparkova, J. (2012). Interactions of DNA with a new platinum(IV) azide dipyridine complex activated by UVA and visible light: Relationship to toxicity in tumor cells. Chem. Res. Toxicol. 25, 1099-1111.

40)Tai, H.-C., Brodbeck, R., Kasparkova, J., Farrer, N.J., Brabec, V., Sadler, P.J., and Deeth, R.J. (2012). Combined theoretical and computational study of interstrand DNA guanine-guanine cross-linking by trans-[Pt(pyridine)2] derived from the photoactivated prodrug trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2]. Inorg. Chem. 51, 6830-6841.

41)Suchankova, T., Kubicek, K., Kasparkova, J., Brabec, V. and Kozelka, J. (2012) Platinum-DNA interstrand crosslinks: Molecular determinants of bending and unwinding of the double helix. J Inorg Biochem, in press, doi: 10.1016/j.jinorgbio.2011.1009.1025.

42)Muchova, T., Quintal, S.M., Farrell, N.P., Brabec, V. and Kasparkova, J. (2012) Antitumor bifunctional dinuclear PtII complex BBR3535 forms interduplex DNA cross-links under molecular crowding conditions. J Biol Inorg Chem, 17, 239-245

43)Florian, J., Kasparkova, J., Farrell, N.P. and Brabec, V. (2012) Thermodynamic stability and energetics of DNA duplexes containing major intrastrand cross-links of second generation antitumor dinuclear PtII complexes. J Biol Inorg Chem, 17, 187-196

44)Stepankova, J., Studenovsky, M., Malina, J., Kasparkova, J., Liskova, B., Novakova, O., Ulbrich, K. and Brabec, V. (2011) DNA interactions of 2-pyrrolinodoxorubicin, a distinctively more potent daunosamine-modified analog of doxorubicin. Biochem Pharmacol, 82, 227–235.

45)Olivova, R., Kasparkova, J., Vrana, O., Vojtiskova, M., Suchankova, T., Novakova, O., He, W., Guo, Z. and Brabec, V. (2011) Unique DNA binding mode of antitumor trinuclear tridentate platinum(II) compound. Mol Pharmaceutics, 8, 2368-2378.

46)Malina, J., Kasparkova, J., Farrell, N.P. and Brabec, V. (2011) Walking of antitumor bifunctional trinuclear PtII complex on double-helical DNA. Nucleic Acids Res, 39, 720-728.

47)Kostrhunova, H., Malina, J., Pickard, A.J., Stepankova, J., Vojtiskova, M., Kasparkova, J., Muchova, T., Rohlfing, M.L., Bierbach, U. and Brabec, V. (2011) Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair. Mol Pharmaceutics, 8, 1941-1954.

48)Kisova, A., Zerzankova, L., Habtemariam, A., Sadler, P.J., Brabec, V. and Kasparkova, J. (2011) Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand. Mol Pharmaceutics, 8, 949-957.

49)Zerzankova, L., Kostrhunova, H., Vojtiskova, M., Novakova, O., Suchankova, T., Lin, M., Guo, Z., Kasparkova, J. and Brabec, V. (2010) Mechanistic insights into antitumor effects of new dinuclear cis PtII complexes containing aromatic linkers. Biochem Pharmacol, 80, 344–351.

50)Zerzankova, L., Suchankova, T., Vrana, O., Farrell, N.P., Brabec, V. and Kasparkova, J. (2010) Conformation and recognition of DNA modified by a new antitumor dinuclear PtII complex resistant to decomposition by sulfur nucleophiles. Biochem Pharmacol, 79, 112-121.

51)Novakova, O., Malina, J., Suchankova, T., Kasparkova, J., Bugarcic, T., Sadler, P.J. and Brabec, V. (2010) Energetics, conformation, and recognition of DNA duplexes modified by monodentate RuII complexes containing terphenyl arenes. Chem Eur J, 16, 5744-5754.

52)Kostrhunova, H., Kasparkova, J., Gibson, D. and Brabec, V. (2010) Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione. Mol Pharmaceutics, 7, 2093-2102.

53)Kostrhunova, H., Vrana, O., Suchankova, T., Gibson, D., Kasparkova, J. and Brabec, V. (2010) Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro. Chem Res Toxicol, 23, 1833-1842.

54)Kasparkova, J., Suchankova, T., Halamikova, A., Zerzankova, L., Vrana, O., Margiotta, N., Natile, G. and Brabec, V. (2010) Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring PtII chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand. Biochem Pharmacol, 79, 552-564.

55)Biton, A., Ezra, A., Kasparkova, J., Brabec, V. and Yavin, E. (2010) DNA photocleavage by DNA and DNA-LNA amino acid-dye conjugates. Bioconjugate Chem, 21, 616-621.

56)Alkhader, S., Ezra, A., Kasparkova, J., Brabec, V. and Yavin, E. (2010) A metal-free DNA nuclease based on a cyclic peptide scaffold. Bioconjugate Chem, 21, 1425-1431.

57)Suchankova, T., Vojtiskova, M., Reedijk, J., Brabec, V. and Kasparkova, J. (2009) DNA and glutathione interactions in cell-free media of asymmetric platinum(II) complexes cis- and trans-[PtCl2(isopropylamine)(1-methylimidazole)]: relations to their different antitumor effects. J Biol Inorg Chem, 14, 75-87.

58)Ruhayel, R.A., Moniodis, J.J., Yang, X., Kasparkova, J., Brabec, V., Berners-Price, S.J. and Farrell, N.P. (2009) Factors affecting DNA-DNA interstrand cross-links in the antiparallel 3'-3' sense: A comparison with the 5'-5' directional isomer. Chem Eur J, 15, 9365-9374.

59)Nováková, O., Malina, J., Kašpárková, J., Halámiková, A., Bernard, V., Intini, F., Natile, G. and Brabec, V. (2009) Energetics, conformation, and recognition of DNA duplexes modified by methylated analogues of [PtCl(dien)]+. Chem Eur J, 15, 6211-6221.

60)Krause-Heuer, A.M., Grunert, R., Kuhne, S., Buczkowska, M., Wheate, N.J., Le Pevelen, D.D., Boag, L.R., Fisher, D.M., Kasparkova, J., Malina, J. et al. (2009) Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells. J Med Chem, 52, 5474–5484.

61)Heringova, P., Kasparkova, J. and Brabec, V. (2009) DNA adducts of antitumor cisplatin preclude telomeric sequences from forming G-quadruplexes. J Biol Inorg Chem, 14, 959-968.

62)Brabec, V. and Kasparkova, J. (2009) Role of DNA repair in antitumor effects of platinum drugs. In Hadjiliadis, N. and Sletten, E. (eds.), Metal Complex - DNA Interactions. Wiley, Chichester, UK, pp. 175-208.

63)Kasparkova, J., Heringova, P., Brabec, V., Mackay, F. and Sadler, P.J. (2008) Photoactivated DNA modifications by platinum(IV) azide complex in cell-free media. In Collery, P., Maymard, I., Theophanides, T., Khassanova, L. and Collery, T. (eds.), Metal Ions in Biology and Medicine. John Libbey Eurotext, Montrouge, Vol. 10, pp. 463-469.

64)Kasparkova, J., Marini, V., Bursova, V. and Brabec, V. (2008) Biophysical studies on the stability of DNA intrastrand cross-links of transplatin. Biophys J, 95, 4361-4371.

65)Kasparkova, J., Vojtiskova, M., Natile, G. and Brabec, V. (2008) Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chem Eur J, 14, 1330-1341.

66)Hegmans, A., Kasparkova, J., Vrana, O., Kelland, L.R., Brabec, V. and Farrell, N.P. (2008) Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity. J Med Chem, 51, 2254-2260.

67)Halámiková, A., Heringová, P., Kašpárková, J., Intini, F.P., Natile, G., Nemirovski, A., Gibson, D. and Brabec, V. (2008) Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine. J Inorg Biochem, 102, 1077–1089.

68)de Mier-Vinue, J., Gay, M., Montana, A.M., Saez, R.-I., Moreno, V., Kasparkova, J., Vrana, O., Heringova, P., Brabec, V., Boccarelli, A. et al. (2008) Synthesis, biophysical studies, and antiproliferative activity of platinum(II) complexes having 1,2-bis(aminomethyl)carbobicyclic ligands. J Med Chem, 51, 424-431.

69)Castellano-Castillo, M., Kostrhunova, H., Marini, V., Kasparkova, J., Sadler, P., Malinge, J.-M. and Brabec, V. (2008) Binding of mismatch repair protein MutS to mispaired DNA adducts of intercalating ruthenium(II) arene complexes. J Biol Inorg Chem, 13, 993-999.

70)Bugarcic, T., Habtemariam, A., Stepankova, J., Heringova, P., Kasparkova, J., Deeth, R.J., Johnstone, R.D.L., Prescimone, A., Parkin, A., Parsons, S. et al. (2008) The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes. Inorg Chem, 47, 11470-11486.

71)Bugarcic, T., Novakova, O., Halamikova, A., Zerzankova, L., Vrana, O., Kasparkova, J., Habtemariam, A., Parsons, S., Sadler, P.J. and Brabec, V. (2008) Cytotoxicity, cellular uptake, and DNA interactions of new monodentate ruthenium(II) complexes containing terphenyl arenes. J Med Chem, 51, 5310-5319.

72)Moriarity, B., Novakova, O., Farrell, N., Brabec, V. and Kasparkova, J. (2007) 1,2-GG intrastrand cross-link of antitumor dinuclear bifunctional platinum compound with spermidine linker inhibits DNA polymerization more effectively than the cross-link of conventional cisplatin. Arch Biochem Biophys, 459, 264-272.

73)Mackay, F.S., Woods, J.A., Heringova, P., Kasparkova, J., Pizarro, A.M., Moggach, S.A., Parsons, S., Brabec, V. and Sadler, P.J. (2007) A potent cytotoxic photoactivated platinum complex. Proc Natl Acad Sci USA, 104, 20743-20748.

74)Halamikova, A., Vrana, O., Kasparkova, J. and Brabec, V. (2007) Biochemical studies of the thermal effects on DNA modifications by the antitumor cisplatin and their repair. ChemBioChem, 8, 2008-2015.

75)Gallmeier, E., Hucl, T., Brody, J.R., Dezentje, D.A., Tahir, K., Kasparkova, J., Brabec, V., Bachman, K.E. and Kern, S.E. (2007) High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer Res, 67, 2169-2177.

76)Chvalova, K., Brabec, V. and Kasparkova, J. (2007) Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res, 35, 1812-1821.

77)Brabec, V., Christofis, P., Slamova, M., Kostrhunova, H., Novakova, O., Najajreh, Y., Gibson, D. and Kasparkova, J. (2007) DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)]. Biochem Pharmacol, 73, 1887-1900.

78)Stehlíková, K., Kašpárková, J., Nováková, O., Martínez, A., Moreno, V. and Brabec, V. (2006) Recognition of DNA modified by trans-[PtCl2NH3(4-hydroxymethylpyridine)] by tumor suppressor protein p53 and character of DNA adducts of this cytotoxic complex. FEBS J, 273, 301-314.

79)Pivonkova, H., Brazdova, M., Kasparkova, J., Brabec, V. and Fojta, M. (2006) Recognition of cisplatin-damaged DNA by p53 protein: Critical role of the p53 C-terminal domain. Biochem Biophys Res Commun, 339, 477-484.

80)Najajreh, Y., Khazanov, E., Jawbry, S., Ardeli-Tzaraf, Y., Perez, J.M., Kasparkova, J., Brabec, V., Barenholz, Y. and Gibson, D. (2006) Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies. J Med Chem, 49, 4665-4673.

81)Najajreh, Y., Ardeli-Tzaraf, Y., Kasparkova, J., Heringova, P., Prilutski, D., Balter, L., Jawbry, S., Khazanov, E., Perez, J.M., Barenholz, Y. et al. (2006) Interactions of platinum complexes containing cationic, bicyclic, nonplanar piperidinopiperidine ligands with biological nucleophiles. J Med Chem, 49, 4674-4683.

82)Kasparkova, J., Novakova, O., Vrana, O., Intini, F., Natile, G. and Brabec, V. (2006) Molecular aspects of antitumor effects of a new platinum(IV) drug. Mol Pharmacol, 70, 1708-1719.

83)Heringova, P., Woods, J., Mackay, F.S., Kasparkova, J., Sadler, P.J. and Brabec, V. (2006) Transplatin is cytotoxic when photoactivated: Enhanced formation of DNA cross-links. J Med Chem, 49, 7792-7798.

84)Chválová, K., Kašpárková, J., Farrell, N. and Brabec, V. (2006) Deoxyribonuclease I footprinting reveals different DNA binding modes of bifunctional platinum complexes. FEBS J, 273, 3467-3478.

85)Brabec, V., Stehlikova, K., Malina, J., Vojtiskova, M. and Kasparkova, J. (2006) Thermodynamic properties of damaged DNA and its recognition by xeroderma pigmentosum group A protein and replication protein A. Arch Biochem Biophys, 446, 1-10.

86)Bodo, J., Hunakova, L., Kvasnicka, P., Jakubikova, J., Duraj, J., Kasparkova, J. and Sedlak, J. (2006) Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations. Brit J Cancer, 95, 1348-1353.

87)Novakova, O., Kasparkova, J., Bursova, V., Hofr, C., Vojtiskova, M., Chen, H., Sadler, P.J. and Brabec, V. (2005) Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA-binding proteins and repair. Relationship to cytotoxicity. Chem Biol, 12, 121-129.

88)Najajreh, Y., Kasparkova, J., Marini, V., Gibson, D. and Brabec, V. (2005) Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand. J Biol Inorg Chem, 10, 722-731.

89)Najajreh, Y., Prilutski, D., Ardeli-Tzaraf, Y., Perez, J.-M., Khazanov, E., Barenholz, Y., Kasparkova, J., Brabec, V. and Gibson, D. (2005) Structure and unique interactions with DNA of a cationic trans-platinum complex with the nonplanar bicyclic piperidinopiperidine ligand. Angew Chem Int Ed, 44, 2-4.

90)Marini, V., Christofis, P., Novakova, O., Kasparkova, J., Farrell, N. and Brabec, V. (2005) Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of antitumor trans-[PtCl2(NH3)(thiazole)]. Nucleic Acids Res, 33, 5819-5828.

91)Bursova, V., Kasparkova, J., Hofr, C. and Brabec, V. (2005) Effects of monofunctional adducts of platinum(II) complexes on thermodynamic stability and energetics of DNA duplexes. Biophys J, 88, 1207-1214.

92)Brabec, V. and Kasparkova, J. (2005) Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updates, 8, 131-146.

93)Brabec, V. and Kasparkova, J. (2005) DNA interactions of platinum anticancer drugs. Recent advances and mechanisms of action. In Perez-Martin, J.-M., Fuertes, M. A. and Alonso, C. (eds.), Metal Compounds in Cancer Chemotherapy. Research Signpost, Trivandrum, Kerala (India), pp. 187-218.

94)Brabec, V. and Kasparkova, J. (2005) Platinum-based drugs. In Gielen, M. and Tiekink, E. R. T. (eds.), Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine. John Wiley & Sons, Ltd, Chichester, pp. 489-506.

95)Prokop, R., Kasparkova, J., Novakova, O., Marini, V., Pizarro, A.M., Navarro-Ranninger, C. and Brabec, V. (2004) DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand. Biochem Pharmacol, 67, 1097-1109.

96)Kloster, M., Kostrhunova, H., Zaludova, R., Malina, J., Kasparkova, J., Brabec, V. and Farrell, N. (2004) Trifunctional dinuclear platinum complexes as DNA-protein cross-linking agents. Biochemistry, 43, 7776-7786.

97)Kasparkova, J., Vrana, O., Farrell, N. and Brabec, V. (2004) Effect of the geometry of the central coordination sphere in antitumor trinuclear platinum complexes on DNA binding. J Inorg Biochem, 98, 1560-1569.